SHR4640

Unknown / undisclosed

Phase 3complete

Evidence outlook · registrational

Gout: registrational trials complete

No completed mid-stage readout is on record. Its registrational studies have completed. Check News and the registry record for topline outcomes.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Gout
NCT04956432 · Jiangsu HengRui Medicine Co., Ltd.
2021-06-15 – 2024-08-23 · Gout
What this study did
NCT04052932 · Jiangsu HengRui Medicine Co., Ltd.
2019-07-16 – 2021-07-14 · Gout
What this study did
Phase 2 (4)
Gout
NCT07362355 · Jiangsu HengRui Medicine Co., Ltd.
2026-02-09 – 2027-07 · Primary Gout and Hyperuricemia
What this study did
NCT05513976 · Jiangsu HengRui Medicine Co., Ltd.
2022-09-15 – 2023-09-20 · Primary Gout and Hyperuricemia
What this study did
Other / comorbidity
NCT04180982 · Jiangsu HengRui Medicine Co., Ltd.
2019-12-03 – 2020-08-30 · Hyperuricemia
What this study did
NCT03185793 · Jiangsu HengRui Medicine Co., Ltd.
2017-07-20 – 2018-07-20 · Hyperuricemia
What this study did
Phase 1 (14)
Gout
NCT06196580 · Jiangsu HengRui Medicine Co., Ltd.
2024-01-04 – 2024-02-16 · Gout and Hyperuricemia
What this study did
NCT04586803 · Jiangsu HengRui Medicine Co., Ltd.
2020-10 – 2020-12 · Primary Gout, Hyperuricemia
What this study did
NCT03211403 · Atridia Pty Ltd.
2017-07-04 – 2018-02-15 · Gout, Hyperuricemia
What this study did
NCT03131583 · Jiangsu HengRui Medicine Co., Ltd.
2017-02-17 – 2018-01-29 · Gout
What this study did
NCT02890966 · Jiangsu HengRui Medicine Co., Ltd.
2016-07 – 2017-03 · Gout; Hyperuricemia
What this study did
NCT02815839 · Jiangsu HengRui Medicine Co., Ltd.
2015-11 – 2017-02 · Gout; Hyperuricemia
What this study did
NCT03015948 · Atridia Pty Ltd.
2016-09-22 – 2016-11-23 · Gout
What this study did
Other / comorbidity
NCT05954169 · Jiangsu HengRui Medicine Co., Ltd.
2023-08-07 – 2024-07-01 · Hyperuricemia
What this study did
NCT06168929 · Jiangsu HengRui Medicine Co., Ltd.
2023-12-13 – 2024-01-13 · Hyperuricemia
What this study did
NCT04305392 · Jiangsu HengRui Medicine Co., Ltd.
2020-08-04 – 2022-12 · Hepatic Impairment
What this study did
NCT04850638 · Jiangsu HengRui Medicine Co., Ltd.
2021-06-28 – 2021-09-14 · Healthy Male Subjects
What this study did
NCT04620408 · Jiangsu HengRui Medicine Co., Ltd.
2020-12 – 2021-02 · Healthy Subjects
What this study did
NCT04157959 · Jiangsu HengRui Medicine Co., Ltd.
2019-10-14 – 2020-06-30 · Hyperuricemia
What this study did
NCT04260373 · Jiangsu HengRui Medicine Co., Ltd.
2020-03-19 – 2020-04-03 · Healthy Adult Male Volunteers
What this study did

Competitive landscape

Other URAT1 (urate transporter 1, SLC22A12) drugs

Lingdolinurad. Compare all 2 URAT1 (urate transporter 1, SLC22A12) drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
SHR4640: this drugPhase 3UndisclosedURAT1 (urate transporter 1, SLC22A12)not yet gradedNo reviewed efficacy summary
Lingdolinurad
Phase 2(overall)
Small moleculeURAT1 (urate transporter 1, SLC22A12)not yet gradedNo reviewed efficacy summary

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow SHR4640 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
July 2027 (1)
Phase 2GoutRecruiting
Est. primary completion 2027-07 · NCT07362355 · CT.gov ↗
What to watch

See the full readout calendar ↗